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BACKGROUND: Sunitinib malate (SUTENT) has promising single-agent activity given on Schedule 4/2 (4 weeks on treatment followed
by 2 weeks off treatment) in advanced non-small cell lung cancer (NSCLC).
METHODS: We examined the activity of sunitinib on a continuous daily dosing (CDD) schedule in an open-label, multicentre phase II
study in patients with previously treated, advanced NSCLC. Patients X18 years with stage IIIB/IV NSCLC after failure with platinum-
based chemotherapy, received sunitinib 37.5mg per day. The primary end point was objective response rate (ORR). Secondary end
points included progression-free survival (PFS), overall survival (OS), 1-year survival rate, and safety.
RESULTS: Of 47 patients receiving sunitinib, one patient achieved a confirmed partial response (ORR 2.1% (95% confidence interval
(CI) 0.1, 11.3)) and 11 (23.4%) had stable disease (SD) X8 weeks. Five patients had SD46 months. Median PFS was 11.9 weeks
(95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7). The 1-year survival probability was 38.4% (95% CI 24.2, 52.5).
Treatment was generally well tolerated.
CONCLUSIONS: The safety profile and time-to-event analyses, albeit relatively low response rate of 2%, suggest single-agent sunitinib on
a CDD schedule may be a potential therapeutic agent for patients with advanced, refractory NSCLC.
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Vascular endothelial growth factor (VEGF) and the platelet-
derived growth factor (PDGF) signalling pathways are critical
components in the pathogenesis of non-small cell lung cancer
(NSCLC) (Koukourakis et al, 1997; Yuan et al, 2001; Shikada et al,
2005). Clinical data with the anti-VEGF monoclonal antibody,
bevacizumab, plus first-line chemotherapy improved efficacy in
patients with advanced NSCLC (Sandler et al, 2006; Manegold et al,
2007, 2008), indicating that targeting angiogenesis through VEGF
is a viable strategy. Furthermore, preclinical data suggest that
concomitant inhibition of VEGF and PDGF signalling may
improve antitumour activity compared with VEGF inhibition
alone (Shikada et al, 2005; Potapova et al, 2006; Hasumi et al,
2007).
Sunitinib is an oral multitargeted tyrosine kinase inhibitor of
VEGF receptors (VEGFRs 1–3) and PDGF receptors (PDGFRs a
and b), as well as other receptor types, and is approved
multinationally for the treatment of advanced renal cell carcinoma
(RCC) and imatinib-resistant or -intolerant gastrointestinal
stromal tumours (GISTs) (Abrams et al, 2003; Mendel et al,
2003; Murray et al, 2003; O’Farrell et al, 2003; Kim et al, 2006). In
preclinical studies, sunitinib decreased tumour growth in NSCLC
NCI-H460 xenograft models, with tumour growth inhibition
ranging from 56 to 85% (Christensen, 2008). Further, in a phase
II trial of single-agent sunitinib, we reported an objective response
rate (ORR) of 11.1% (95% confidence interval (CI) 4.6, 21.6) in
heavily pretreated patients with advanced NSCLC. Median
progression-free survival (PFS) was 12.0 weeks (95% CI 10.0,
16.1) and overall survival (OS) was 23.4 weeks (95% CI 17.0, 28.3).
Sunitinib was administered intermittently at 50mg per day on
Schedule 4/2 (4 weeks on treatment followed by 2 weeks off
treatment) and was well tolerated (Socinski et al, 2008).
Following reports from a phase II sunitinib study in metastatic
breast cancer (Burstein et al, 2008) suggesting that some patients
had increases in the size of the superficial lesions during the
2-week off-treatment period, it was hypothesised that better
tumour control could be achieved with sunitinib given once daily
on a continuous daily dose (CDD) schedule. Although CDD
and Schedule 4/2 have not been compared head-to-head in
one trial, subsequent trials of sunitinib using a CDD schedule
in patients with RCC and with GIST indicate that this regimen
is well tolerated, associated with broadly similar clinical activity
to Schedule 4/2, and provides flexibility in dosing schedule
(GIST: median PFS 34 weeks and 24 weeks for sunitinib on CDD
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sand Schedule 4/2, respectively; RCC: median PFS 8.2 months for
both sunitinib on CDD and Schedule 4/2) (Motzer et al, 2006, 2007;
George et al, 2007, 2009; Escudier et al, 2009). Here we report the
efficacy and safety of sunitinib 37.5mg per day given as a CDD
schedule in an additional cohort of patients, after failure of a
platinum-based regimen.
MATERIALS AND METHODS
Study population
Patients 18 years or older, with Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1 and histologically
proven stage IIIB (with pleural or pericardial effusion) or stage IV
NSCLC were recruited. All patients had received previous
treatment with no more than two chemotherapy regimens (at
least one platinum based), had unidimensional measurable disease
at baseline, and evidence of disease progression within 6 months of
their most recent prior systemic anticancer treatment.
Patients were excluded if they had a history of, or known, brain
metastases; gross haemoptysis (45ml per episode or 410ml
per day) o4 weeks before start of study; hypertension (4160/
90mmHg) that could not be controlled with standard antihyper-
tensive agents; cardiac disease, cerebrovascular accident or
pulmonary embolism; left ventricular ejection fraction (LVEF)
that was below the lower limit of normal; cardiac dysrhythmias of
National Cancer Institute (NCI) Common Terminology Criteria for
Adverse Events (CTCAE) grade X2; atrial fibrillation of any grade;
prolongation of the QTc interval (4450ms for males or 4470ms
for females); previous treatment with an antiangiogenic agent,
including thalidomide or inhibitors of PDGFR (previous treatment
with gefitinib or erlotinib was permitted); or grade 3 haemorrhage
o4 weeks before start of study.
Study design and treatment
This open-label, multicentre, phase II trial conducted in the
United States and Europe analysed sunitinib administered on
Schedule 4/2 and on a CDD schedule. Investigations of the
two treatment schedules were performed in separate cohorts
of patients. Patients in the CDD cohort were recruited from
the same study sites at which the Schedule 4/2 was analysed,
after completion of enrolment in the Schedule 4/2 cohort and
observation of the requisite number of responses on Schedule 4/2.
Results from the Schedule 4/2 cohort have been published
(Socinski et al, 2008).
Patients received once-daily sunitinib in 4-week cycles at a
starting dose of 37.5mg per day. Dose escalation was permitted to
50mg per day after two cycles (first 8 weeks of treatment) if
patients experienced grade p1 non-haematologic toxicity or grade
p2 haematologic toxicity attributed to sunitinib. Patients experi-
encing sunitinib-related toxicity requiring treatment interruption
or dose reduction (NCI-CTCAE grade 3/4) could receive a reduced
dose (25mg per day). Treatment was administered for up to 13
cycles or until disease progression or withdrawal of consent.
Patients deriving clinical benefit after completing 13 cycles could
continue to receive sunitinib through participation in a separate
protocol.
The study was approved by the institutional review board of
each participating centre and carried out in accordance with the
International Conference on Harmonisation Good Clinical Practice
guidelines, and applicable local laws and regulatory requirements.
Study assessments
The primary end point was objective response as measured by the
confirmed ORR, defined as the proportion of patients with a
confirmed complete response (CR) or confirmed partial res-
ponse (PR). Response was determined using radiologic tumour
assessments and the Response Evaluation Criteria for Solid
Tumours (RECIST) (Therasse et al, 2000). Secondary end points
included PFS, OS, and 1-year survival rate. Tumour imaging,
including CT or MRI scans of the chest, abdomen, and pelvis
and other applicable sites of disease, was performed on day 1 of
even-numbered cycles, whenever disease progression was sus-
pected, to confirm a CR or PR (at least 4 weeks after initial
documentation of response), and at the end of study treatment or
withdrawal from the study (if an assessment was not performed
within the previous 6 weeks). Tumour scans were not reviewed
centrally.
Safety assessments included physical examinations, laboratory
tests, vital signs, and 12-lead electrocardiogram (ECG). Adverse
events (AEs) and serious AEs (SAEs) were graded according to
the NCI-CTCAE version 3.0. Pharmacokinetic (PK) para-
meters analysed included plasma trough concentrations at
steady-state for sunitinib, its primary active metabolite, SU12662,
and sunitinib plus SU12662 (total drug), determined on day 1 of
cycles 1–13.
Statistical analysis
Depending on the number of objective responses observed on
Schedule 4/2, sample size for the CDD cohort was determined
using either a two-stage design (if p5 confirmed objective
responses were observed) or a single-stage design (if X6
confirmed objective responses were observed). As there were
seven confirmed objective responses on Schedule 4/2, the sample
size on the CDD schedule was based on a single-stage design with
an a level of 10 and 80% power. This design required 44 patients to
test the null hypothesis that the true response rate was p5% vs the
alternative hypothesis that the true response rate was X15%. At
the end of the study, if X5 objective tumour responses were
observed on the CDD schedule, then the null hypothesis was to be
rejected. The study population for efficacy and safety analyses
included all patients enrolled into the study who received at least
one dose of sunitinib.
RESULTS
Patient characteristics
In total, 47 patients were enrolled into the CDD cohort. The first
patient entered the study in November 2005, and the last patient
entered the study and received sunitinib in May 2006; baseline
characteristics are summarised in Table 1. The median age of
patients was 60 years, and most patients were male (n¼27, 57.4%),
smokers (n¼40, 85.1%), and had an ECOG performance status
of 0 or 1 (n¼46, 97.8%). Most patients (57.5%) had adeno-
carcinoma. Commonly reported sites of disease included the lung,
lymph nodes, bone, and liver. Of the six patients with stage IIIB
disease, four had pleural effusion. In total, 28 patients (59.6%) had
received at least two previous systemic regimens.
Exposure to study drug
Of the 47 patients included in the analyses, nine patients
discontinued treatment during cycle 1 because of AEs (n¼4) or
disease progression (n¼5). Overall, patients received a median
of three treatment cycles (range: 1–12) and was administered
sunitinib for a median of 68 days (range: 11–331).
Dosing modifications were required in 15 patients (31.9%),
including 14 patients (29.8%) with dose reductions to 25mg and
one patient with dose escalation to 50mg (as permitted per
protocol). Dose interruption occurred in 17 patients (36.2%); the
most frequently reported reason for dose interruptions and delays
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swas AEs (n¼14 patients, 29.8%), including hypertension (n¼5,
10.6%), nausea, fatigue, and skin reaction (each: n¼3, 6.4%).
Treatment discontinuation was primarily due to disease progres-
sion (n¼34, 72.3%). In addition, 12 patients (25.5%) discontinued
because of AEs; for six of these patients, AEs were considered to be
related to study treatment and included lymphopenia, peripheral
neuropathy, respiratory failure, vomiting (all n¼1, grade 3),
asthenia, skin toxicity (both n¼1, grade 2), and fatigue (n¼2,
grade 2). One patient discontinued in order to receive sunitinib on
a continuation protocol (no other patients continued to receive
sunitinib after study end on a continuation protocol). Seven
patients (15%) received at least 9 cycles of sunitinib therapy, and
the longest duration of treatment in this study was 12 cycles
(approximately 1 year).
Efficacy
One patient achieved a confirmed PR (ORR: 2.1%, 95% CI 0.1, 11.3;
Figure 1) observed at cycle 8 and confirmed at cycle 10; the
duration of response was 24.4 weeks. This patient (64-year-old
white male) had stage IV adenocarcinoma with lung metastases
and received 12 cycles of sunitinib (37.5mg per day reduced to
25mg per day in cycles 2 onwards because of grade 3 skin reaction
and hypertension). Eleven patients (23.4%) showed stable disease
(SD) (X8 weeks), which lasted for 43 months in 10 patients (one
of whom had received previous therapy with gefitinib). Of these 10
patients, five had SD for 46 months. Of the five patients with
SD46 months, all had stage IV disease and tumour types included
adenocarcinoma (one patient with bone metastases and the second
with lung metastases), squamous cell carcinoma (liver metastases),
large cell carcinoma (liver metastases), and large cell neuroendo-
crine carcinoma (with lung metastases). These patients received
7–12 cycles of sunitinib (two patients received dose reductions
from 37.5 to 25mg per day in cycles 2 or 3 for the duration of study
treatment).
The median PFS was 2.7 months (11.9 weeks, 95% CI 8.6, 14.1;
Figure 2A) and median OS was 8.6 months (37.1 weeks, 95% CI
31.1, 69.7; Figure 2B). The 1-year survival was 38.4% (95% CI 24.2,
52.5).
Safety
The most commonly reported AEs (all causality) were generally
mild-to-moderate (grade 1/2) in severity (Table 2). Grade 3/4 AEs
included fatigue/asthenia (17.0%), hypertension (8.5%), and
dyspnoea (6.4%; Table 2). Four patients (8.7%) experienced grade
3 neutropenia, while no patients experienced febrile neutropenia
or grade X3 anaemia or thrombocytopenia. Two subjects
experienced grade 3 bleeding events (haemoptysis and gastric
haemorrhage, respectively); neither was assessed to be related to
study drug. The haemoptysis was reported in a 78-year-old white
male patient with stage IV squamous cell carcinoma with lung
metastases with a history of gastroesophageal reflux disease who
received sunitinib 37.5mg per day for 2 cycles. The patient
recovered without sequelae. No subjects reported grade 4 or 5
bleeding events.
The most common AEs attributed to sunitinib treatment were
diarrhoea (n¼13, 27.7%), fatigue (n¼13, 27.7%), hypertension
(n¼11, 23.4%), and erythema (n¼10, 21.3%). Seven patients died
on study (within 28 days of receiving the last dose of study
medication), including four patients who died because of disease
progression and one patient because of clinical deterioration
(49-year-old male, 22 days after the first dose). One patient died
because of pulmonary embolism (72-year-old male with stage IIIB
squamous cell carcinoma and pleural effusion, and comorbidities
of controlled chronic obstructive pulmonary disease and hyper-
cholesterolaemia). He was admitted to hospital after developing
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Figure 1 Best response for target lesions by patient, based on maximal
percentage of tumour reduction.
Table 1 Baseline demographic and disease characteristics
Sunitinib
(N¼47)
Age in years, median (range) 60.0 (37.0–81.0)
Male/female, n (%) 27 (57.4)/20 (42.6)
ECOG PS 0/1, n (%) 22 (46.8)/24 (51.1)
a
Smoking status, n (%)
Ever smoked 40 (85.1)
Never smoked 5 (10.6)
Not known 2 (4.3)
NSCLC histology, n (%)
Adenocarcinoma 25 (53.2)
Squamous cell carcinoma 7 (14.9)
Large cell carcinoma 3 (6.4)
Bronchioloalveolar 2 (4.3)
Other 10 (21.3)
Disease stage, n (%)
IIIB 6 (12.8)
IV 41 (87.2)
Metastatic sites, n (%)
Lung 34 (72.3)
Lymph nodes 23 (48.9)
Bone 16 (34.0)
Liver 13 (27.7)
Other
b 26 (55.3)
Previous chemotherapy, n (%) 47 (100)
Carboplatin 28 (59.6)
Cisplatin 23 (48.9)
Gemcitabine 19 (40.4)
Docetaxel 17 (36.2)
Paclitaxel 13 (27.7)
Pemetrexed 13 (27.7)
Other 8 (17.0)
Maximum number of previous regimens, n (%)
Chemotherapy 1/2/42 (%) 22 (46.8)/23 (48.9)/2 (4.3)
EGFR inhibitor
c 1/2 (%) 12 (25.5)/1 (2.1)
Total 1/2/42 (%) 19 (40.4)/18 (38.3)/10 (21.3)
Abbreviations: ECOG PS¼Eastern Cooperative Oncology Group performance
status; NSCLC¼non-small cell lung cancer.
aOne patient had an ECOG PS¼2.
bOther comprise pleural effusion (n¼11), adrenal gland, soft tissues, viscera (each
n¼4), peritoneum, skin, and other (each n¼1).
cCetuximab, erlotinib, or gefitinib.
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sdyspnea with accompanying bronchospasm approximately 2
months after starting sunitinib 37.5mg per day, and approxima-
tely 1 week after dose reduction to 25mg per day because of nausea
and vomiting. Chest radiograph revealed increased left haemo-
thorax opacity with pleural effusion, and lung collapse. Pulmonary
embolism (unrelated to study treatment) as well as disease
progression was noted on chest CT and the patient died 1 day
later. An 81-year-old male patient with no known cardiac history
received sunitinib 37.5mg per day for large cell neuro-
endocrine lung cancer for approximately 7.5 months when
he developed dyspnoea and weakness, with pulmonary infiltra-
tes present on chest radiograph. He received diuretics with
no improvement and the following day experienced a cardiac
arrest and died because of treatment-related congestive heart
failure.
Pharmacokinetics
Steady-state trough plasma concentrations of sunitinib and
SU12662 were observed throughout the study. The median trough
plasma concentration ranges of sunitinib and SU12662 across
treatment cycles were 31–56 and 11–18ngml
–1, respectively. The
median steady-state plasma trough concentration of sunitinib
and SU12662 combined was approximately 50ngml
–1 and was
consistent across cycles (44–73ngml
–1), providing no evidence
of drug accumulation over treatment cycles.
DISCUSSION
Aberrant signalling in multiple pathways has a critical role in the
pathogenesis of NSCLC. Inhibition of a specific, single pathway
may stimulate activation of another to resume growth of the
tumour and/or its associated blood vessels. Co-inhibition of VEGF
and PDGF pathways potentially offers greater antiangiogenic effect
than inhibition of either pathway alone (Potapova et al, 2006).
However, it is possible that broader antitumour activity may also
translate into a less favourable safety profile due to off-target
toxicity.
Favourable antitumour activity and tolerability data with single-
agent sunitinib, an inhibitor of VEGFRs and PDGFRs, in the
intermittent (Schedule 4/2) dose cohort of this trial were reported
earlier (Socinski et al, 2008). The CDD schedule was analysed to
provide flexibility in the dosing schedule and was based on the
hypothesis that better tumour control could be achieved with
sunitinib given on a CDD schedule.
In this CDD cohort, analysing sunitinib 37.5mg per day in
patients with advanced platinum-refractory NSCLC, SD (X8
weeks) and PR were observed in 11 patients and 1 patient,
respectively. The frequency of liver (n¼4, 33%) and bone (n¼3,
25%) metastases at baseline observed in the 12 patients with SD or
PR was similar to that reported in the overall CDD cohort (28 and
34%, respectively).
This phase II trial was not designed to compare the antitumour
activity observed on Schedule 4/2 and the CDD schedule. A higher
ORR was observed on Schedule 4/2 (11.1%) vs CDD (2.1%), and a
higher median OS was observed on the CDD schedule (37.1 vs 23.4
weeks, respectively). Median PFS was similar on both treatment
schedules (12.0 and 11.9 weeks). Although the ORR (2.1%)
observed in the CDD cohort did not meet the pre-specified
criterion required to reject the null hypothesis, the observed OS
and PFS suggest that CDD of sunitinib provides clinical benefit to
patients with advanced NSCLC.
Table 2 Incidence (%) of the most common (X10%) treatment-
emergent (all-causality) non-haematologic AEs
Sunitinib (N¼47)
Adverse event
a
Grade 3
n (%)
Grade 4
n (%)
Total
b
n (%)
Fatigue/asthenia 7 (14.9) 1 (2.1) 28 (59.6)
Pain/myalgia 1 (2.1) 0 23 (48.9)
Nausea/vomiting 1 (2.1) 0 19 (40.4)
Diarrhoea 0 0 16 (34.0)
Stomatitis/mucosal inflammation 1 (2.1) 0 15 (31.9)
Hypertension 4 (8.5) 0 13 (27.7)
Cough 0 0 12 (25.5)
Dyspnoea 3 (6.4) 0 12 (25.5)
Dysgeusia 0 0 10 (21.3)
Erythema 1 (2.1) 0 10 (21.3)
Dizziness 0 0 9 (19.1)
Dyspepsia 0 0 9 (19.1)
Oedema peripheral 0 0 9 (19.1)
Anorexia/weight decreased 0 0 8 (17.0)
Haemoptysis 1 (2.1) 0 8 (17.0)
Headache 0 0 8 (17.0)
Constipation 0 0 7 (14.9)
Ageusia 0 0 6 (12.8)
Skin reaction 1 (2.1) 0 6 (12.8)
Arthralgia 0 0 5 (10.6)
Abbreviation: AEs¼adverse events.
aAdverse events graded according to
NCI CTCAE v3.0, worst per patient.
bGrade 1–4 AEs (n¼7 grade 5 AEs were
reported).
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Probability of survival at 1 year was 38.4% (95% CI 24.2, 52.5)
Median PFS: 11.9 weeks
(95% Cl 8.6, 14.1)
Median OS: 37.1 weeks
(95% Cl 31.1, 69.7)
Figure 2 (A) Progression-free survival (PFS) and (B) overall survival
(OS) Kaplan–Meier plots. Probability of survival at 1 year was 38.4%
(95% CI 24.2, 52.5).
Phase II study of continuous daily sunutinib dosing
S Novello et al
1546
British Journal of Cancer (2009) 101(9), 1543–1548 & 2009 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sIt is noteworthy that the median PFS (11.9 weeks (2.7 months))
and OS (37.1 weeks (8.6 months)) in the CDD cohort of this trial
are comparable to the currently available treatment options for
this setting as shown in phase III studies, including docetaxel (time
to progression (TTP) 10.6 weeks, OS 7.0 months), erlotinib (PFS
2.2 months, OS 6.7 months), and pemetrexed vs docetaxel (PFS 2.9
months in both arms, OS 8.3 and 7.9 months, respectively),
(Shepherd et al, 2000, 2005; Hanna et al, 2004). Interestingly, PFS
observed with sorafenib monotherapy in this treatment setting was
2.8 months (Gatzemeier et al, 2006). However, caution is required
when interpreting antitumour activity across clinical trials of
different agents with differences in clinical trial design and
baseline characteristics of patients.
The sunitinib AE profile observed in the CDD cohort was
tolerable and manageable. The most frequent treatment-related
AEs were consistent with common conditions associated with
advanced NSCLC and known toxicities of sunitinib. Most were
mild-to-moderate in severity and were managed adequately with
supportive measures, with or without dose modification. Although
formal comparisons cannot be made between the safety profiles of
sunitinib on Schedules 4/2 vs CDD, among the commonly reported
toxicities, constitutional (e.g., fatigue/asthenia: 69.8 vs 59.6%)
and gastrointestinal (e.g., nausea/vomiting: 52.4 vs 40.4%) AEs
appeared to be less frequent on the CDD schedule, notwithstanding
the longer median treatment duration on the CDD schedule
(92 vs 77 days) (Socinski et al, 2008). PK analysis revealed no
evidence of drug accumulation after CDD of sunitinib, and total
drug plasma trough concentrations maintained steady-state levels
across treatment cycles (44–73mgml
–1) at levels known to inhibit
phosphorylation of receptor tyrosine kinases, based on in vivo
studies (Mendel et al, 2003).
In summary, single-agent sunitinib given on a CDD
schedule was associated with an acceptable toxicity profile,
and time-to-event analyses suggest that this regimen may provide
clinical benefit in patients with advanced, refractory NSCLC.
A randomised phase III trial of sunitinib 37.5mg on a CDD
schedule in combination with erlotinib 150mg per day is currently
ongoing.
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